The accumulation of endogenous catecholamines within the extracellular space of the ischemic myocardium has been studied in the isolated perfused (Langendorff) heart of the rat subjected to various periods of complete ischemia, with subsequent collection of the reperfusate. Catecholamines and deaminated metabolites were measured by radioenzymatic methods, or high pressure liquid chromatography. Ischemic periods of less than 10 minutes are not associated with an increased overflow of catecholamines or metabolites. Longer periods of ischemia are accompanied by the overflow of noradrenaline and its deaminated metabolite 3,4-dihydroxyphenylglycol. This overflow increases with lengthening of the preceding ischemic period (10 minutes: 2.5 ± 0.6, 20 minutes: 209.8 ± 17.2, 60 minutes: 1270.5 ± 148.1 pmol noradrenaline/g heart).
THE importance of the sympathetic nervous system in modulating the course of myocardial ischemia has been demonstrated both in clinical (Multicentre international study, 1975; Peter et al., 1978; Yusuf et al., 1980; Norwegian multicenter study group, 1981; Hjalmarson et al., 1981 ; Beta-blocker heart attack trial research group, 1982) and experimental studies (Maling et al., 1959; Schaal et al., 1969) . This modulation has been shown both with regard to infarct size (Reimer et al., 1976) and the occurrence of arrhythmias (Ebert et al., 1970; Menken et al., 1979; Schwartz et al., 1980) . However, a quantitative assessment of the extracellular accumulation of noradrenaline within the myocardium during ischemia of varying durations is not available. Similarly, the relative contributions of locally and centrally mediated release of noradrenaline to the total accumulation are not known. Therefore, in the present studies, these aspects of the interrelationship between the sympathetic nervous system and myocardial ischemia were investigated, using the isolated perfused heart of the rat.
Methods
Rats (Wistar strain) weighing 150-200 g were anesthetized with thiobutabarbital (50 mg/kg, ip). The peritoneal cavity was opened and 0.1 ml heparin (500 U) was injected into the inferior vena cava. The thorax was opened and the hearts were rapidly removed, weighed, and the aortas cannulated. All hearts underwent an initial perfusion with a modified Krebs-Henseleit solution (KHS) at 5 ml/g heart per min for 30 minutes. The composition of KHS in mM; Na + , 144.14; K + , 4.02; Ca ++ , 1.85; Mg ++ , 1.05; Cl", 139.8; PO 4 B , 0.44; HCO 3 -, 11.9; pyruvate, 1.82; glucose, 11.1; EDTA, 0.027. The perfusate was gassed with oxygen and the pH adjusted to 7.4 with carbon dioxide. The temperature of the perfusate was adjusted to 37.5°C at the point of entry into the aorta and the hearts suspended in humidified warmed (37.5°C) chambers. The efficacy of myocardial temperature regulation during ischemia was demonstrated by measurement of the intramyocardial temperature, with a fine temperature-sensitive probe. The hearts were subsequently subjected to various periods of global and total ischemia and then reperfused at 5 ml/g heart per min. Samples for catecholamine estimation were taken from the coronary venous effluent before ischemia and during the reperfusion period. The concentrations of catecholamines in the perfusate were measured either by means of electrochemical detection following high pressure liquid chromatography (HPLC) separation in series 1, or by a radioenzymatic method (Da Prada and Ziircher, 1976) in all other series of experiments. The pharmacological agents used in this study [cocaine (Merck) , corticosterone (Fluka), desipramine (Ciba-Geigy), lidocaine (Astra), nisoxetine (Eli Lilly), (+)-oxaprotiline (Ciba-Geigy), yohimbine (Serva)] were dissolved in ethanol, with final concentrations of ethanol being less than 0.05%, which is far below the ethanol concentration influencing the spontaneous or stimulation-induced release of noradrenaline (Gothert and Thielecke, 1976) . The drugs (or the solvent only, in the control experiments) were added to the perfusate 20 minutes prior to ischemia and continued to the end of the experiment.
Experimental Series
Series 1 Figure 1 : noradrenaline (NA); Figure 2 : adrenaline (A) and 3,4-dihydroxyphenylglycol (DOPEG).
Ischemia: 5, 15, 30 and 60 minutes (each group n = 10). Effluent collections: last minute before ischemia, and 1st, 2nd, 3rd, 4th, 5th, 10th, and 15th minute of reperfusion.
Perfusate: Krebs-Henseleit solution (KHS) without drug. HPLC analysis.
Series 2 Figure 3 : noradrenaline. Ischemia: 2, 10, 20, and 60 minutes (each time, n = 12). Effluent collection: cumulative 5 minutes before and 5 minutes after.
Perfusate: KHS without (n = 24) and with cocaine 30 tiM (n = 24). Radioenzymatic analysis.
Series 3 Table 1 : noradrenaline, adrenaline, and dopamine (DA). Ischemia: 5, 10, 15, 20, 30, 40 , and 60 minutes. Effluent collection: cumulative 5 minutes before and 5 minutes after.
Perfusate: KHS without and with desipramine (DMI) 100 nM.
Radioenzymatic analysis.
Series 4 Figure 4 : noradrenaline. Ischemia: 20 minutes. Effluent collection: cumulative 5 minutes before and 5 minutes after.
Perfusate: KHS with varying concentrations of desipramine (0 M, 100 pM, 1 nM, 10 nM, 100 nM, and 1 fiht) (each group «=7).
Series 5 Figure 5 : noradrenaline. Ischemia: 20 minutes. Effluent collection: cumulative 5 minutes before and 5 minutes after.
Perfusate: KHS without drug (n = 7), with nisoxetine, 100 nM (n = 7), with oxaprotttine, 300 nM (n = 7), with Circulation Research/Vo/. 55, No. 5, November 1984 yohimbine 1 /*M (n = 7), with lidocaine, 10 /IM (n = 7). Radioenzymatic analysis.
Series 6 Figure 6 : noradrenaline. Ischemia: 20 minutes. Effluent collection: cumulative 5 minutes before and 5 minutes after.
Perfusate: KHS without (« = 7) and with corticosterone 30 AIM (n = 7), KHS + desipramine, 100 nM, without (« = 7) and with corticosterone, 30 /IM (n = 7).
Series 7 Figure 7 : noradrenaline. Ischemia: 20 minutes. Effluent collection: cumulative 5 minutes before and 5 minutes after.
Perfusate: normal KHS (Ca ++ , 1.85 HIM) (n = 7), Ca ++free KHS (5 minute preperfusion) (n = 7), Ca ++ -free KHS (20 minute preperfusion) (« = 7), Ca ++ -free KHS + EGTA 1 irtM (20 minute preperfusion) (« = 7).
Radioenzymatic analysis. Table 2 : noradrenaline, adrenaline, and dopamine. Ischemia: 10, 20, 40, and 60 min (each time, n = 14). Effluent collection: cumulative 5 minutes before and 5 minutes after.
Series 8
Perfusate: Ca ++ -free KHS (20 minute preperfusion) without (n = 28) and with desipramine, 100 nM (« = 28).
Series 9 Figure 8 : heart rate, developed tension. Ischemia: 30 minutes. Measurement of heart rate and tension. Perfusate: KHS without drug (n = 6), KHS with desipramine, 100 nM (n = 6), Ca ++ -free KHS {n = 6).
Measurement of Tension. In series 9, the tension developed by the heart and the rate of contraction was recorded according to the method of Nayler (1979) : A force-displacement transducer (Grass FTO3C) was attached to the ventricular apex via a thread and an atraumatic needle. After amplification of the signal by a carrier amplifier (San-ei 6M41, carrier frequency 5000 Hz), it was displayed on a recorder (San-ei Recti-Horiz-8K).
At the start of the experiment, pretension was adjusted to 500 dyn in all hearts. Developed tension was calculated as the difference between systolic peak tension (at phasic contraction) or continuous tension (at contracture) and the preset tension.
Biochemical Methods

Radioenzymatic Assay
The samples were put on ice, immediately stabilized by addition of perchloric acid, and stored at -80°C. Radioenzymatic determinations of concentrations of noradrenaline, adrenaline, and dopamine were performed according to the method of Da Prada and Zurcher (1976) . The intraassay coefficient of variation was less than 5%, the interassay coefficient of variation, less than 10%. Cocaine at 30 IIM, corticosterone at 30 (OA, desipramine at concentrations from 100 pM to 1 /IM, lidocaine at 10 IIM, nisoxetine Schomig et a/./Catecholamine Release in Myocardial Ischemia 691 at 100 riM, oxaprotiline at 300 nM, and yohimbine at 1 /*M were without effect on blanks or on the estimation of standard concentrations of catecholamines.
HPLC Separation and Electrochemical Detection
The samples were collected into tubes cooled to -60°C by means of a metal block placed in dry ice. Samples were stored at -80°C until assayed. Before thawing an internal standard, dihydroxybenzylamine (DBA), and 0.1 ml of an antioxidant mixture containing EDTA (100 HIM) and dithiothreitol (2 HIM) were added to each 3-ml sample. The pH was adjusted to 8.4 by addition of 100 /il of 1 M Tris buffer (pH 8.5). Catecholamines and deaminated metabolites were adsorbed on aluminum oxide column containing 18 mg acid washed A1 2 O 3 (Eriksson and Persson, 1982) . After two washings with distilled water, the catecholamines were eluted with 300 n\ of 0.2 M phosphoric acid. One hundred microliters of the eluate were injected into the HPLC system. Separation was performed with a Cis 5-^m reversed phase column (Latek), the solvent being 0.2 M phosphate buffer, pH 2.7, containing EDTA (40 ^M) and octylsulfate (100 HM). Quantitative analysis was performed by electrochemical detection (BAS LC 4B). The retention times of the catecholamines and their metabolites were: noradrenaline 5.0 minutes; adrenaline, 9.1 minutes; dopamine, 24.2 minutes; DOPEG, 4.1 minutes; 3,4dihydroxymandelic (DOMA), 3.0 minutes; DBA (internal standard), 11.2 minutes. Calculations of the concentrations included correction for recovery by relation to the internal standard (Davis, 1981) . The limit of detection was 0.4 pmol/ml for noradrenaline, adrenaline, and DOPEG, 0.8 pmol/ml for DOMA and 2 pmol/ml for dopamine. The coefficients of variation were 8.4% for noradrenaline, 8.5% for adrenaline, 11.8% for dopamine, 8.7% for DO-PEG, and 13.3% for DOMA.
Statistical Methods
Statistical evaluation was by analysis of variance or by paired f-test. Results are expressed as means ± SEM. Fig. 3 
Results
Dependence of Catecholamine Overflow on the Duration of the Preceding Ischemia (Table 1,
)
The overflow of the catecholamines noradrenaline, adrenaline, and dopamine (measured radioenzymatically) after various periods of total myocardial ischemia (series 3) is given in the top section of Table  1 . The values represent the cumulative overflow from the heart per gram heart weight during a 5minute period of reperfusion following stop flow. Ischemic periods of 10 minutes result in no increase in noradrenaline overflow in comparison to the control (preischemic) values. Ischemic periods of 15 minutes and longer result in a progressive increase of noradrenaline overflow, more than 1 nmol noradrenaline per g heart after 60 minutes of total ischemia.
The overflow of adrenaline and dopamine amounts to less than 5% of the corresponding noradrenaline overflow. Adrenaline is detected in the coronary venous effluent after ischemic periods of 15 minutes and longer. Dopamine is not found after ischemic periods of less than 20 minutes. Figure 3 shows, on a logarithmic scale, the cumulative overflow of noradrenaline (radioenzymatically measured) during a 5-minute period of reperfusion after 2, 10, 20, and 60 minutes of myocardial ischemia (series 2). The open bars represent the values obtained with Krebs Henseleit solution without addition of cocaine. The values of noradrenaline overflow are in good agreement with those given above in Table 1 . Again, a progressive increase of noradrenaline overflow is observed when ischemia 15.5 ± 1.8 n = 56 n = 7 n = 14 n=7 n = 7 n = 7 n = 7 n = 7 Overflow of noradrenaline (NA), adrenaline (A), and dopamine (DA) from isolated perfused rat hearts (n = 112) during a 5-minute control period before ischemia and during the first 5 minutes of reperfusion after total ischemia of varying duration (5, 10, 15, 20, 30, 40 , 60 minutes) without (top section) and with (bottom section) blockade of neuronal uptake with 100 nM desipramine (DMI). ND = not detectable by radioenzymatic assay; mean values ± SEM. * P < 0.05 (perfusion with DMI vs. without DMI).
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is prolonged for more than 10 minute. The values are 3.5 ± 0.4 pmol/g for the control period, 3.7 ± 0.5 for 2, 6.6 ± 1.3 for 10, 250.4 ± 63.0 for 20, and 1319.8 ± 174.5 pmol/g for 60 minutes of total ischemia. In contrast to series 3, the noradrenaline overflow after 10 minutes ischemia is slightly, but significantly (p < 0.05), higher than control values.
Time Course of Catecholamine Overflow during Reperfusion (Figs. 1 and 2)
The results of experiments in which the overflow of catecholamines and metabolites were determined by HPLC separation and electrochemical detection are shown in Figures 1 and 2 . The time courses of the noradrenaline overflow after ischemic periods of 5, 15, 30, and 60 minutes are illustrated ( Fig. 1) . No overflow of endogenous noradrenaline can be detected during the preischemic perfusion period. There is also no noradrenaline overflow detectable by this method after an ischemic period of 5 minutes. Following a stop flow ischemia of 15 minutes, 23.3 ± 3.9 pmol/g noradrenaline are detected during the first minute of reperfusion. This value increases to 278.6 ± 28.6 pmol/g after a 30-minute period of ischemia, and to 871.0 ± 152.3 pmol/g after a 60minute period of ischemia. After each period of ischemia, there is a continuous decay in the amount of noradrenaline released with the bulk being washed out during the first 5 minutes of reperfusion.
No detectable amounts of adrenaline are found with the HPLC method after 5, 15, or 30 minutes of ischemia ( Fig. 2 ). Adrenaline is detectable in significant amounts only after 60 minutes of ischemia (26.6 ± 4 . 1 pmoi during the first minute of reperfusion). Dopamine cannot be detected by the HPLC method during the reperfusion phase after ischemic periods of 5, 15, 30, or 60 minutes. DOPEG, the main deaminated metabolite of noradrenaline and adrenaline, is not detectable during normal perfusion nor during the washout period after 5 minutes of ischemia. Prolongation of the ischemic period to 15, 30, and 60 minutes results in a progressive overflow of this metabolite from the ischemic hearts. During the first minute of reperfusion, 7.9 ± 2.6 pmol/g are detected after a 15-minute period of ischemia, 15.8 ± 4.1 pmol/g after a 30minute period of ischemia, and 125.9 ± 23.7 pmol/ g after a 60-minute period of ischemia. DOMA cannot be found during normal perfusion nor after various intervals of stop flow ischemia.
Effects of Neuronal Uptake Blockade on Catecholamine Overflow (Table 1; Figs. 3 and 5)
The lower panel in Table 1 represents values for noradrenaline, adrenaline, and dopamine release after various periods of ischemia in the presence of desipramine (100 nM). Uptake blockade with desipramine has no significant effect on spontaneous noradrenaline overflow during the control period, but leads to a 2-fold increase in noradrenaline overflow after ischemic periods of 5 and 10 minutes. In contrast to the enhancement following short ischemic periods, uptake] blockade causes a reduction of noradrenaline overflow after ischemic periods of 15, 20, 30, and 40 minutes. At 20 and 30 minutes, values amount to less than 20% of those obtained without desipramine. Adrenaline and dopamine overflow are both reduced in a similar fashion at ischemic periods of 20 and 30 minutes. Following myocardial ischemia of 60 minutes, however, cate-cholamine release is not affected by the presence of desipramine.
When uptake] blockade is performed with cocaine (30 MM), similar effects are found (series 2). Addition of cocaine to the perfusate results in an enhanced overflow of noradrenaline after ischemic periods of up to 10 minutes. The cumulative overflow (over a 5-minute period) of endogenous noradrenaline during control conditions increases from 3.5 ± 0.4 to 5.6 ± 0.8 pmol/g heart (P < 0.05), from 3.7 ± 0.5 to 6.5 ± 0.8 pmol/g (P < 0.05) after 2 minutes of ischemia and from 6.6 ± 1.3 to 17.4 ± 2.5 pmol/g (P < 0.01) after 10 minutes of ischemia. However, after 20 minutes of ischemia, noradrenaline overflow is decreased from 250.4 ± 63.0 to 36.3 ± 3.8 pmol/g (P < 0.01). After 60 minutes of ischemia, there is no difference (1319.9 ± 174.5 vs. 1388.3 ± 91.4 pmol/g) in the cumulative noradrenaline overflow between hearts with and without cocaine.
The effects of two other agents blocking neuronal uptake on the ischemia-induced noradrenaline overflow are demonstrated in Figure 5 . The concentrations used (nisoxetine, 100 nM, and (+)-oxaprotiline, 300 nM) are equivalent to 100 nM desipramine relative to their receptor-binding or uptakej-blocking properties (Wong and Bymaster, 1976; Raisman et al., 1982; Waldmeier et al., 1982) . Both agents are as effective in reducing the ischemia-induced noradrenaline release as desipramine and cocaine. The noradrenaline overflow from the heart after 20 minutes of ischemia amounts to 36.8 ± 4.9 pmol/g (P < 0.01) with nisoxetine and to 35.9 ± 2.4 pmol/g (P < 0.01) with (+)-oxaprotiline, compared to 201.8 ± 40.4 pmol/g without uptake] blockade.
Concentration-Related Effect of Desipramine on
Ischemia-Induced Noradrenaline Overflow (Fig. 4 ) Figure 4 shows the effects of various concentrations of desipramine on the noradrenaline release following a 20-minute period of total ischemia. Whereas 100 pM desipramine has no significant effect on noradrenaline release, a dose-dependent reduction is observed when the concentration of desipramine in the perfusate is increased from 1 to 100 nM. Further increase of desipramine concentration of 1 / XM does not result in a further decrease of noradrenaline overflow. A 50% inhibition of the ischemia-induced noradrenaline release is achieved at a concentration of 2.3 ± 1.1 nM desipramine.
Effects of Local Anesthetic and of a 2 -Receptor Blockade on Ischemia-Induced Noradrenaline Overflow (Fig. 5)
The effects of lidocaine (10 /IM) and yohimbine (1 HM) on noradrenaline overflow after 20 minutes of myocardial ischemia are shown in Figure 5 . Neither agent exerts any significant effect on noradrenaline overflow. With lidocaine, the noradrenaline overflow amounts to 205.2 ± 42.6 pmol/g, with yohim-overflow of 2 5 0 , noradrenaline pmol/g 150.
100.
Oj 10-10 10-9 desipramine 10-8 10-7 10-6 M bine to 215.5 ± 28.2 pmol/g, compared to 201.8 ± 40.4 pmol/g without pharmacological intervention. Overflow (Fig. 6 ) Figure 6 shows the effect of blockade of uptake 2 by corticosterone (30 fiu) on the noradrenaline overflow from the heart during 5 minutes of reperfusion after 20 minutes of ischemia. The increase of noradrenaline overflow after uptake 2 blockade is statistically significant (P < 0.05) after additional blockade of uptakej by desipramine (68.8 ± 4.9 vs. 46.0 ± 4.3 pmol/g), but not significant without uptake, blockade (267.3 ± 28.9 vs. 234.0 ± 25.5 pmol/g).
Effects of Blockade of Extraneuronal Uptake (Uptake^ on Noradrenaline
Effects of Calcium-Free Perfusion on
Catecholamine Overflow (Fig. 7; Table 2 ) Perfusion with calcium-free perfusate has no effect on the cumulative overflow of noradrenaline from the rat heart after 20 minutes of ischemia. The overflow is independent of the duration of calciumfree preperfusion (5 minutes: 242.8 ± 34.6 pmol/g; 20 minutes: 252 ± 23.1 pmol/g). Addition of 1 HIM EGTA to the calcium-free perfusate does not influence the overflow of noradrenaline (225.7 ± 17.9 pmol/g) as compared to control perfusion (202;0 ± 15.6 pmol/g) (Fig. 7) . The dependence of catecholamine overflow on the duration of the preceding ischemia remains unaffected when calcium-freeperfused hearts (Table 2 ) are compared to hearts perfused with calcium containing medium ( Table 1) . Addition of 100 nM desipramine to the calcium-free perfusate results in a reduced overflow of catecholamines after periods of ischemia longer than 10 minutes (Table 2) .
Heart Rate and Developed Tension before and during Ischemia (Fig. 8) Heart rate and developed tension remain stable throughout an initial perfusion period of 30 minutes with KHS. After cessation of flow, both heart rate and developed tension decline rapidly, and no spontaneous beats are detectable 6-10 minutes after the start of ischemia. During the following period of ischemia, tension rises gradually because of developing contracture. Half-maximal contracture is achieved after 18.8 ± 0.9 min of ischemia. When 100 nM desipramine is added to the perfusate after an initial perfusion with normal KHS, neither the time course of heart rate nor developed tension is altered before or during ischemia. Half maximal contracture is achieved after 17.9 ± 0.8 min.
When calcium-free perfusion is started after 10 minutes of preperfusion with KHS, developed tension ceased immediately. During ischemia, the development of contracture is retarded significantly (P < 0.05). Half-maximal contracture is delayed to 22.4 ± 0.6 min.
Discussion
Early Release of Noradrenaline
The experiments demonstrate that periods of total ischemia of up to 10 minutes duration are not associated with overflow of catecholamines during the reperfusion phase, and such periods are therefore probably not associated with the accumulation of catecholamines within the extracellular spaces of the myocardium. Ischemic episodes of 10 minutes duration are associated with a small and nonconstant noradrenaline overflow, and this noradrenalinewashout becomes progressively greater with longer periods of ischemia (Table 1 ; Figs. 1 and 3) .
The absence of noradrenaline overflow after short periods of ischemia is in contrast to an earlier study in which short periods of total ischemia (3-4 minutes) in isolated rabbit hearts were found to cause the overflow of large quantities (2700 pmol/g heart) of noradrenaline-like fluorescence (Wollenberger and Shabab, 1965) . Similarly, in in vivo experiments overflow of noradrenaline 300-, pmol/g
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Ca free in dogs, coronary artery occlusions of 2.5 minutes resulted in a net overflow of noradrenaline (73 pmol/g heart) detected in the coronary venous effluent (Shabab and Wollenberger, 1969) . Hirche et al. (1980) found an inconsistent noradrenaline overflow following 3 minutes of ischemia in the anesthetized pig. On the other hand, in a study in the isolated perfused rat heart, Abrahamsson et al. (1981) were unable to find evidence of an early myocardial depletion of noradrenaline. However, in all these studies, noradrenaline was assayed fluoromerrically, a method subsequently shown to be unreliable because of insufficient specificity and sensitivity in comparison to the radioenzymatic and HPLC methods. 
FIGURE 7. Cumulative overflow of endogenous noradrenaline from isolated rat hearts during 5 minutes of reperfusion following 20 minutes of total ischemia. Perfusion with KHS containing 1.85 mM calcium (control), calcium-free perfusion starting 5 minutes before ischemia (group A), starting 20 minute before ischemia (group B), and calcium-free perfusion + 1 mM EGTA starting 20 minutes before ischemia (group O. No significant difference was found between the groups. Mean values ± SEM; each group n = 7.
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To overcome these methodological problems, two independent methods were used in the current experiments to estimate the overflow of noradrenaline, adrenaline, and dopamine from the ischemic rat myocardium. The advantage of using two different methods was to combine the higher sensitivity of the radioenzymatic method with the higher specificity of the HPLC method. Neither of these methods provided evidence of a substantial overflow of noradrenaline within the first 10 minutes of total and global ischemia (Table 1 ; Figs. 1 and 3) .
In other studies in which a radioenzymatic assay had been used to determine the noradrenaline overflow into the coronary venous effluent, 5 minutes of coronary ligation in dogs did not result in a contracture   10  20  30  40  50  60min control -•perfusate2 with desipramine 100nM •-perfusate 2 Ca* * free net overflow of noradrenaline (Me Grath et al., 1981) . Similarly, 11 minutes of myocardial ischemia in dogs did not lead to higher noradrenaline concentrations in the ischemic than in the nonischemic venous effluent, even in combination with left stellate ganglion stimulation (Forfar et al., 1983) . These results are in close agreement with our present results concerning the early noradrenaline release. In vivo models, however, although closer to the clinical situation, have certain disadvantages: the degree of flow reduction in such models is not precisely defined, and flow is not uniform due to the presence of a collateral circulation. Furthermore, collection of venous overflow from cardiac veins includes, to a variable extent, overflow of blood from both ischemic and nonischemic areas, thus making interpretation difficult. On the other hand, the model described in this paper cannot answer questions regarding the release of noradrenaline in response to sympathetic nerve activity, a question which is addressed by .
FIGURE 8. Developed tension and heart rate in isolated perfused rat hearts before and during 30 minutes of total ischemia. The effect of three different perfusates was investigated after 10 minutes of initial perfusion with Krebs-Henseleit solution (KHS) (perfusate V: (V control perfusion (perfusate 2 = KHS) (n = 6), (2) perfusate 2 = KHS containing 100 n\t desipramine (n = 6), (3) perfusate 2 = calcium-free KHS (n = 6). After treatment with desipramine, mechanical action of the hearts was not different from control hearts. Perfusion with calcium-free perfusate resulted in an immediate loss of tension, and the development of ischemia-induced contracture was retarded significantly. Mean values ± SEM
A major advantage of the model chosen is the fact that it is well defined. The results obtained on heart rate and tension during ischemia correspond well with the extensively described time course of cardiac dynamics in a comparable model given by Hearse (1977) . Thus, our data on transmitter release can be related to metabolic events occurring in this model which have been described elsewhere (Hearse et al., 1977; Garlick et al., 1979) . Direct conclusions from the mechanical action of the heart muscle cell to the ischemia tolerance of the sympathetic nerve cell are not possible because of profound quantitative differences in the energy-consuming processes in these different types of cells. Therefore, interventions improving the tolerance to ischemia of the myocardial muscle cell by sparing energy due to decreased mechanical activity do not necessarily have a similar beneficial effect on sympathetic nerve cells within the myocardium.
Release of Noradrenaline Induced by Ischemic Periods of Longer Than 10 Minutes
The depletion of catecholamines from ischemic as well as nonischemic areas of the canine heart was assessed in studies conducted by Matthes and Gudbjarnason (1971) . After 24-hour periods of coronary occlusion, a decrease in cardiac noradrenaline content to less than 10% of the initial value was observed in the infarcted area, and no noradrenaline could be detected within the ischemic myocardium after 4 days. Holmgren et al. (1981) reported a gradual decline in cardiac noradrenaline fluorescence within hours of a coronary artery occlusion in rats. However, these studies do not give information about the time course of catecholamine loss during ischemia, the metabolic fate of the catecholamines, or the concentration of the transmitter in the extracellular compartment of the myocardium potentially available for receptor activation. Similarly, studies in which isolated rat hearts are loaded with radio-labeled noradrenaline and the overflow of radioactivity from the ischemic myocardium subsequently measured (Rochette et al., 1980; Abrahamsson et al., 1983 ) cannot give any quantitative information about the release of endogenous catecholamines during the course of ischemia because of an unknown relation between radiolabeled and endogenous noradrenaline, an unknown rate of metabolism of the radiolabeled transmitter, and an unknown distribution of the radiolabeled compound in intracellular compartments.
A quantitative assessment can be made by measuring the overflow of endogenous noradrenaline during washout. Assuming the prior uniform distribution of noradrenaline within the extracellular spaces of the heart, and assuming an extracellular space of 20%, then 20-30 minutes of total ischemia could be expected to produce an extracellular noradrenaline concentration in excess of 1 HM under the experimental conditions described. This concentration is well within the range known to be capable of producing myocardial necrosis, even in the normally perfused heart (Waldenstrom et al., 1978) .
The overflow of catecholamines during the reperfusion period in these experiments could be due either to washout from the extracellular space of noradrenaline previously released from the sympathetic nerves or to a reperfusion-activated release. The very high concentrations of noradrenaline immediately after the onset of reperfusion, together with the subsequent fast decay (Fig. 1) , strongly suggest that the detected noradrenaline represents, in large part, noradrenaline previously accumulated within the extracellular space which is then washed out during reperfusion.
Adrenaline and dopamine are found during reperfusion after ischemic periods longer than 15 minutes (A) and 20 minutes (DA), respectively (Table  1) . Their quantities amount to less than 5% of the noradrenaline washed out during the same reperfusion period. The ratio between noradrenaline and adrenaline released during ischemia is in the same range as that found in the rat heart (Saavedra et al., 1981) or in the human heart (Petch and Nayler, 1979) . It is only possible to speculate about the source of adrenaline. The presence of phenylethanolamine-N-methyl transferase, the enzyme relevant for adrenaline synthesis in the myocardium (Axelrod, 1962) , makes it conceivable that, besides adrenaline taken up from the systemic circulation, this transmitter can be synthetized in the heart, at least in small amounts.
Possible Mechanisms of Extracellular Catecholamine Accumulation in the Ischemic Myocardium
An accumulation of noradrenaline within the extracellular space of the myocardium represents the net outcome of two opposing processes: (1) the release of noradrenaline from sympathetic nerve terminals, and (2) its removal.
Since, in the experimental model used, there is no ongoing flow during the course of ischemia, removal of liberated noradrenaline must represent an intramyocardial clearance process such as the neuronal uptake (uptakd) or extraneuronal uptake (uptake 2 ) of noradrenaline (Iversen, 1971) , and a decreased activity of clearance mechanisms should result in an enhanced extracellular accumulation of catecholamines.
An increased release of noradrenaline from neurons could be the result of either sympathetic stimulation or of an increased extracellular potassium concentration of more than 15 HIM (Blaustein et al., 1972; Carpenter et al., 1976) . The underlying mechanism for both possibilities is a Ca ++ -dependent exocytosis, (Smith and Winkler, 1972; Blaustein, 1979) which is modulated by presynaptic receptors such as a 2 -receptors (Starke and Montel, 1974; Langer, 1977; .
Another mechanism which might contribute to the noradrenaline release induced by ischemia is increased leakage from intracellular to extracellular compartments due to passive diffusion. However, due to the poor lipid solubility of the predominantly ionized catecholamines (Mack and Bonisch, 1979) , this mechanism can be considered to be important only when the structural integrity of cell membranes is lost because of ischemic damage.
A third mechanism might be a carrier-mediated efflux of catecholamines from the cytoplasm into the extracellular space. This mechanism was postulated by Paton (1973) who, under special experimental conditions (blockade of monoaminoxidase, catechol-O-methyltransferase, and vesicular uptake; subsequent loading with radiolabeled noradrenaline; inhibition of the Na + ,K + -ATPase; or reduction of the extracellular sodium concentration) found an efflux of [ 3 H]noradrenaline from the rabbit atria which could be blocked by cocaine or desipramine. This finding was confirmed by several groups in other experimental models for noradrenaline (Ross and Kelder, 1976; Graefe and Fuchs, 1979; Ross and Kelder, 1979; Bonisch et al., 1983) and for dopamine (Raiteri et al., 1977; Raiteri et al., 1979; Liang and Rutledge, 1982) . Besides the fact that it can be inhibited by various uptake] blockers, this release mechanism is characterized by its independence from extracellular calcium Kelder, 1976, 1979; Bonisch et al., 1983) . No biological significance has so far been attributed to this mechanism, however.
The relative contribution of these different mechanisms to the catecholamine accumulation within the extracellular space of the myocardium may vary during the course of ischemia. From the results of these studies, three subsequent phases of noradrenaline release from the ischemic myocardium can be characterized:
Phase 1 (Up to 10 Minutes of Total Ischemia) During this phase, no increase of spontaneous noradrenaline overflow is found compared to a non- Circulation Research/Vol. 55, No. 5, November 1984 ischemic control period. The transmitter overflow is increased after blockade of neuronal reuptake (Table  1 ; Fig. 3 ).
Sympathetic stimulation during ischemia results in a slightly increased overflow of noradrenaline during reperfusion. This stimulation-induced overflow is enhanced by uptake blockade and/or blockade of presynaptic a 2 -receptors, but does not reach the levels obtained by stimulation during nonischemic conditions . The release of catecholamines shows the same characteristic during phase 1 of ischemia as during a nonischemic period. A significant accumulation of catecholamines in the extracellular space of the ischemic myocardium is prevented by a functioning neuronal uptake. (A more detailed discussion of phase 1 is found in . During this second phase, a progressive increase of the overflow of catecholamines (Table 1) , especially of noradrenaline ( Fig. 3) , is observed. This release is independent from extracellular calcium ( Fig. 7 ; Table 2 ). It is neither modulated by local anesthetics, by « 2 -antagonists ( Fig. 5 ), nor electrical stimulation .
On the other hand, agents blocking neuronal reuptake are capable of reducing the ischemia-induced catecholamine overflow by more than 80% (Table 1; Figs. 3 and 5) . This effect is caused by uptake]-blocking agents, which are structurally unrelated and which are not transported by the carrier, such as cocaine, desipramine, nisoxetine, and oxaprotiline. In our preparation, the effect of desipramine on the catecholamine release is dose dependent with an IC 50 of 2.3 nM (Fig. 4) . This is in the same dose range as both the inhibition constant of desipramine for noradrenaline uptake into synaptosomes of rat brain (Koe, 1976) and the binding constant of desipramine at membranes of rat heart and cortex cells (Raisman et al., 1982) .
Unspecific effects such as inhibition of calmodulin require doses 10,000-fold higher than needed for uptakei blockade (Roufogalis, 1983) . Modulation of metabolic events of ischemia by desipramine can be excluded from the unchanged time course of mechanical activity of the heart during ischemia (Fig.  8) .
Blockade of the extraneuronal uptake with corticosterone (Iversen and Salt, 1970) increases the ischemia-induced noradrenaline overflow from the heart by approximately 20 pmol/g (Fig. 6) .
These facts exclude most of the above-mentioned mechanisms as the cause of the catecholamine release during phase 2: The exocytotic release of catecholamines is absolutely dependent on the presence of extracellular calcium (Rubin, 1970; Baker and Knight, 1978) . However, the present experiments demonstrate the complete independence of ischemia-induced catecholamine overflow from extracellular calcium. Moreover, whereas exocytotic noradrenaline release is modulated by a 2 -antagonists such as yohimbine (Starke et al., 1975; Langer, 1977; , this is not the case for the ischemia-induced noradrenaline overflow . In contrast to the increasing effect on noradrenaline overflow of uptake] blockers when release is exocytotic, the blockade of uptake results in a reduction of catecholamine overflow during ischemia.
Overflow of noradrenaline from the heart induced by passive diffusion of the transmitter out of the neuron would not have been diminished by uptakei blockade. If a reduction of neuronal inactivation had caused the increase in noradrenaline overflow, then a further enhancement would have been expected after blockade of neuronal uptake, which is the main elimination mechanism of extracellular noradrenaline (Iversen, 1971 ). However, the opposite effect has been observed during phase 2.
An explanation for the enhanced noradrenaline release during phase 2 is a carrier-mediated efflux of catecholamines from the sympathetic varicosities. Since active cation-dependent membrane transport systems potentially operate in both directions (Crane, 1977) , it is conceivable that the neuronal uptake carrier is identical with the efflux carrier. Under nonischemic conditions, this carrier provides the inward transport of released noradrenaline, energetically dependent on an intact transmembrane Na + gradient with high extracellular and low intracellular concentrations (White, 1976; Sammet and Graefe, 1979) . Such carrier-mediated efflux mechanism has been described, not only for catecholamines, but also for the aminoacids, glycine and alanine (Schultz and Curran, 1970; Crane, 1977) , for sugars (Crane, 1977) , and for 6-hydroxytryptamine (Nelson and Rudnick, 1979) .
The characteristics of the local metabolic catecholamine release during periods of ischemia between 10 and 40 minutes are in accordance with the characteristics described for a carrier-mediated efflux.
In our model, the outward transport of catecholamines cannot be inhibited by local anesthetics (Paton, 1973; Kelder, 1976, 1979) (Fig. 5) . It is independent from extracellular calcium (Wakade and Kirpekar, 1974; Ross and Kelder, 1976 , 1979 , Bonisch et al., 1983 (Fig. 7 ; Table 2 ). It can be inhibited effectively by uptake] blockade (Paton, 1973; Kelder, 1976, 1979; Graefe and Fuchs, 1979; Bonisch et al., 1983) . The part of release inhibited by uptake] blockade is 67% at 15, 85% at 20, 81% at 30, and 60% at 40 minutes of ischemia.
The main prerequisite for a carrier-mediated efflux across the axoplasmatic membrane is an increased cytoplasmatic concentration of catecholmines (Paton, 1976) . Under normoxic conditions, this cytoplasmatic transmitter concentration is low because of the activity of two mechanisms, both of which are compromised during ischemia: (1) the oxidative deamination catalyzed by monoaminoxidase depends on oxygen (Tipton, 1975) , and (2) the transport of catecholamines into the storage vesicles 699 depends on an intact proton gradient across the vesicle membrane (Philips and Apps, 1980; Knoth et al., 1981) which is disturbed by the lack of high energy phosphates (Casey et al., 1977) and the cytoplasmatic acidosis during ischemia (Garlick et al., 1979) .
The efflux may be facilitated by additional factors (Paton, 1976) , such as decreased transmembrane gradient of sodium, an increased extracellular potassium concentration, and a changed membrane potential which will develop during ischemia (Kleber, 1983) . However, the quantitative influences of these factors, the metabolic prerequisites, and the mechanisms of catecholamine efflux from storage vesicles are not elucidated by the present experiments, and remain an object for further studies.
Other mechanisms, such as exocytosis induced by increased extracellular potassium concentration (Hirsche et al., 1980) and leakage (especially at longer ischemic periods), may contribute, to a minor extent, to the observed catecholamine overflow during this phase.
Phase 3 (Periods of Total Ischemia Longer than 40 Minutes)
This last phase is characterized by a further increase in the spontaneous overflow of catecholamines which cannot be modulated by blockade of the uptake] carrier. Studies of permeability and morphology reveal a progressive injury of membrane structures after ischemic periods of 60 minutes or longer (Ganote et al., 1976) which may cause the observed leakage of catecholamines out of the sympathetic neurons.
Time Course of Catecholamine Release
The time course of the three phases of catecholamine release depends on the conditions of myocardial ischemia. Although total ischemia in vitro is assumed to be a good model of severe ischemia in vivo (Jennings et al., 1981) , the time course of catecholamine release from isolated hearts cannot be extrapolated directly to the in vivo conditions. In situations of variable and incomplete myocardial ischemia (e.g., in vivo experimental myocardial ischemia and human myocardial infarction), it is conceivable that a similar, but temporally dispersed, release would occur. The mechanisms postulated to account for this release would be expected to apply also to incomplete ischemia, but with a more protracted time course. Thus, in situations of heterogenous reduction in myocardial blood flow, different areas of ischemic myocardium (with different residual flows) could be simultaneously at different phases of noradrenaline release. Such heterogeneity, however, would be difficult to investigate in "in vivo" models of myocardial ischemia, since areas of myocardium at different phases of catecholamine release may be topographically close and drain into the same veins. Furthermore, uptake] blockade will have opposite effects on noradrenaline release in different parts of the ischemic zone.
In conclusion, the data demonstrate a catecholamine accumulation in the extracellular compartment during myocardial ischemia. The increase in local noradrenaline concentration within the still viable myocardium (Jennings et al., 1981) may be responsible for a further deterioration of myocardial function during the ischemic process, i.e., acceleration of cell damage and induction of arrhythmias. Different mechanisms of extracellular noradrenaline accumulation have been demonstrated to operate during the course of ischemia. Among them, the carrier-mediated efflux of noradrenaline appears to be of major significance. It is the first time that this mechanism of catecholamine release has been demonstrated to play a key role under pathophysiological conditions such as myocardial ischemia.
